1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer
    Meeting Abstract

    Petrylak, D. P.; Perez, R. P.; Zhang, J.; Smith, D. C.; Ruether, J. D.; Sridhar, S. S.; Sangha, R. S.; Lang, J. M.; Heath, E. I.; Merchan, J. R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Dynamics of immune-mediated thyroid dysfunction in patients with advanced renal cell carcinoma receiving checkpoint inhibitor therapy
    Meeting Abstract

    Osorio, J. C.; Patil, S.; Coskey, D. T.; Carlo, M. I.; Feldman, D. R.; Hellmann, M. D.; Voss, M. H.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Grünwald, V.; Hutson, T. E.; Porta, C.; Powles, T.; Eto, M.; Dutcus, C. E.; Baig, M. A.; Dutta, L.; Li, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update
    Meeting Abstract

    Naing, A.; Infante, J. R.; Hecht, J. R.; Papadopoulos, K. P.; Wong, D. J. L.; Autio, K. A.; Falchook, G. S.; Patel, M. R.; Ott, P. A.; Patnaik, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer
    Meeting Abstract

    Naing, A.; Infante, J. R.; Wong, D. J. L.; Korn, W. M.; Aljumaily, R.; Papadopoulos, K. P.; Autio, K. A.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma
    Meeting Abstract

    Miao, D.; Margolis, C.; Martini, D.; Mullane, S. A.; Cullen, D.; Horak, C.; Wind-Rotolo, M.; Hellmann, M. D.; Voss, M. H.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1 169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Vogelzang, N.; Sartor, O.; Armour, A.; Groaning, M.; Robarts, A.; Petrylak, D. P.; Tolcher, A. W.; Gordon, M. S.; Babiker, H. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC)
    Meeting Abstract

    McKay, R. R.; Werner, L.; Jones, A.; Choudhury, A. D.; Pomerantz, M.; Sweeney, C.; Bubley, G. J.; Slovin, S. F.; Morris, M. J.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy
    Meeting Abstract

    Ku, K. P.; Lang, J. M.; Sperger, J.; Dehm, S.; Kohli, M.; Wang, L.; Wang, L.; Tagawa, S. T.; Scher, H. I.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients
    Meeting Abstract

    Ku, G. Y.; Sanchez-Vega, F.; Chatila, W.; Margolis, M.; Fein, C.; Ilson, D. H.; Hechtman, J. F.; Tuvy, Y.; Bouvier, N.; Kundra, R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save